Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pegfilgrastim

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,435,344Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1 Neulasta/Peglasta

    02 7G-Lasta

    03 9Neulasta

    04 6Neulasta/Peglasta

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 2,293

    2019 Revenue in Millions : 3,221

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 253

    2019 Revenue in Millions : 233

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 39

    2019 Revenue in Millions : 36

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,734

    2020 Revenue in Millions : 2,293

    Growth (%) : -24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 248

    2020 Revenue in Millions : 253

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 45

    2020 Revenue in Millions : 39

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Neulasta/Peglasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta/Peglasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 42

    2021 Revenue in Millions : 45

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 235

    2021 Revenue in Millions : 248

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Neulasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : Neulasta

    U.S.A
    arrow
    Fi Europe 2024
    Not Confirmed

    Amgen

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 1,126

    2021 Revenue in Millions : 1,734

    Growth (%) : -35

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : G-Lasta

    Pegfilgrastim

    arrow
    Fi Europe 2024
    Not Confirmed

    Brand Name : G-Lasta

    Japan
    arrow
    Fi Europe 2024
    Not Confirmed

    Kyowa Kirin

    Pegfilgrastim

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 215

    2022 Revenue in Millions : 235

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF